Global Point of Care Molecular Diagnostics Industry: Key Statistics and Insights in 2025-2033
Summary:
- The global point of care molecular diagnostics market size reached USD 4.0 Billion in 2024.
- The market is expected to reach USD 8.7 Billion by 2033, exhibiting a growth rate (CAGR) of 8.78% during 2025-2033.
- North America leads the market, accounting for the largest point of care molecular diagnostics market share.
- Assays and kits exhibit a clear dominance in the market due to their essential role in facilitating rapid, accurate, and easy-to-use testing in POC settings.
- Polymerase chain reaction (PCR) represents the largest segment because of its high sensitivity, specificity, and widespread use in detecting a broad range of pathogens in POC diagnostics.
- Wet anaerobic digestion remains a dominant segment in the market, allowing for better methane production and more consistent energy generation.
- The rising incidence of infectious diseases globally is driving the need for point of care (POC) diagnostic services.
- Ongoing advancements, particularly in the miniaturization of molecular diagnostic devices, are propelling the growth of the market.
Industry Trends and Drivers:
- Increasing Prevalence of Infectious Diseases:
The adoption of POC diagnostics is increasing as a result of disease rates around the world. Such diseases require rapid diagnosis so that patients can begin receiving treatment. This is made possible through POC testing because they provide results within an hour, rather than a laboratory test. This speed returns more control over disease transmission and improves patient outcomes. Furthermore, POC molecular diagnostics do not require specialized laboratories to work well. Therefore, they are invaluable for implementing disease control especially for areas that are hard to reach or low in income. For this reason, healthcare providers are increasingly choosing the application of POC molecular diagnostics for disease identification.
- Technological Advancements and Miniaturization:
Today’s innovations are expanding, and especially in the biomolecular diagnostic label. Every day new technologies such as microfluidics, lab-on-chip, smart phone apps, point of care PCR enable POC diagnostic kits to be designed and manufactured to be even smaller, easier to use. The level of performance offered by these devices is comparable to clinical laboratory equipment delivering molecular testing. The great thing about these devices is that diagnostic testing can be done from the patient’s side, from the clinic or anywhere. This advancement in technology has made molecular diagnostics more portable thanks to other aspects of the technology, not just to the laboratory that adopts it.
- Growing Demand for Personalized Medicine:
Personalized medicine remains the biggest driver for this market. Of all, it tailors treatments according to the genetic structure and certain diseases alone. This requires reliable and efficient diagnostic tools. Point-of-care (POC) molecular diagnostics fulfills this need. It quickly establishes the genotype, infection along with mutations. This is helpful in creating personalized treatments. For example, in cancer treatment, these tests identify genetic changes on the DNA of the tumor. This aids doctors in deciding the right course of treatment. This is because; when treatments are tailored to meet specific customer needs they are very effective and have very low risk. This results in better patient health. Therefore, the demand for POC molecular diagnostics is increasing. This is because there is a push towards personalization of healthcare delivery and the ability to create fast and accurate diagnostic tools.
Request for a sample copy of this report: https://www.imarcgroup.com/point-of-care-molecular-diagnostics-market/requestsample
Point of Care Molecular Diagnostics Market Report Segmentation:
By Product and Services:
- Assays and Kits
- Instruments and Analyzers
- Software and Services
Assays and kits exhibit a clear dominance in the market due to their essential role in facilitating rapid, accurate, and easy-to-use testing in POC settings.
By Technology:
- Polymerase Chain Reaction (PCR)
- Hybridization
- DNA sequencing
- Microarray
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Others
Polymerase chain reaction (PCR) represents the largest segment because of its high sensitivity, specificity, and widespread use in detecting a broad range of pathogens in POC diagnostics.
By Application:
- Infectious Diseases
- Oncology
- Hematology
- Prenatal Testing
- Endocrinology
- Others
Infectious diseases hold the biggest market share as POC molecular diagnostics are crucial for the timely detection and management of these diseases, particularly in outbreak scenarios.
By End User:
- Physicians’ Offices
- Hospitals and ICUs
- Research Institutes
- Others
On the basis of the end user, the market has been segregated into physicians’ offices, hospitals and ICUs, research institutes, and others.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America dominates the market attributed to its advanced healthcare infrastructure, high adoption rates of new technologies, and strong presence of key industry players.
Top Point of Care Molecular Diagnostics Market Leaders:
The point of care molecular diagnostics market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:
- Abbott Laboratories
- Becton Dickinson and Company
- Binx Health Inc.
- Co-Diagnostics Inc.
- F. Hoffmann-La Roche Ltd
- Gene STAT Molecular Diagnostics LLC
- Hemocue AB (Danaher Corporation)
- Meridian Bioscience Inc.
- Molbio Diagnostics Private Limited
- Quidel Corporation
- Siemens Healthcare GmbH (Siemens AG)
- Thermo Fisher Scientific Inc.
- Visby Medical Inc.
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1–631–791–1145
